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Autoinflammatory diseases include disorders with a monogenic cause and also
complex conditions associated to polygenic or multifactorial factors. An increased
number of both monogenic and polygenic autoinflammatory conditions have been
identified during the last years. Although skin manifestations are often predominant
in monogenic autoinflammatory diseases, clinical and histopathological information
regarding their dermatological involvement is still scarce. Monogenic autoinflammatory
diseases with cutaneous expression can be classified based on the predominant
lesion: (1) maculopapular rashes or inflammatory plaques; (2) urticarial rashes; (3)
pustular, pyogenic or neutrophilic dermatosis-like rashes; (4) panniculitis or subcutaneous
nodules; (5) vasculitis or vasculopathy; (6) hyperkeratotic lesions; (7) hyperpigmented
lesions; (8) bullous lesions; and (9) aphthous lesions. By using this classification, this
review intends to provide clinical and histopathological knowledge about cutaneous
involvement in monogenic autoinflammatory diseases.
Keywords: monogenic autoinflammatory diseases, autoinflammatory diseases, clinical dermatology,
maculopapular rash, urticarial rash, dermatopathology, classification
INTRODUCTION
The term “autoinflammatory diseases” was first used in 1999 to describe a group of rare diseases
of the innate immunity presenting with recurrent episodes of uncontrolled systemic inflammation
(1). Since then, the number of monogenic autoinflammatory conditions and other complex and
polygenic disorders driven by autoinflammatory mechanisms have been in continuous expansion
(2, 3). In addition, several autoimmune diseases and primary immunodeficiencies have been found
to share pathogenic features with autoinflammatory diseases (4, 5).
The most frequent and well-known autoinflammatory mechanism is mediated by the
inflammasomes, intracellular protein complexes acting as innate immune system receptors
with an important role in the sensing of intracellular pathogen- and danger-associated
molecular patterns. They are involved in the susceptibility to infection, autoinflammation,
and tumorigenesis. Inflammasomes consist of a sensor part (the NOD-like-receptor), an
adaptor protein (ASC), and caspase-1 as the downstream effector. Upon stimulation,
inflammasome assembles and activates caspase-1 which cleaves pro-IL-1β and pro-IL-18 into
IL-1β and IL-18. NRLP3 and pyrin inflammasomes are responsible for cryopyrin-associated
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periodic syndromes (CAPS) and familial Mediterranean fever
(FMF), respectively, and other inflammasomopathies (6, 7).
Other relevant inflammasomes include NLRP1 andNLRP4 (8, 9).
Other pathogenic mechanisms causing autoinflammatory
disorders include those related with the activation of NF-κB
transcription factor and type I interferon (IFN) (6, 10). The
transcription factor NF-κB is involved in processes related to
inflammation, cellular differentiation, metabolism, cell survival,
and acquired immune responses (6). In its inactive form, NF-
κB is tied to inhibitors of kBs (IkBs). NF-κB can be activated by
two mechanisms: the canonical pathway, induced by cytokines
and toll-like receptors (TLR), and the non-canonical pathway,
triggered by TNF-receptor family proteins. Both are controlled
by the ubiquitin system. The canonical mechanism is regulated
by K63 and linearMet1 ubiquitin chains. Both proteins are linked
to their substrates (RIPK-1, which is one of the adaptor proteins
on the TNF receptor 1, and IKKγ, part of the IKK complex)
by LUBAC complex (composed by the proteins HOIP, HOIL-1,
and SHARPIN), which increases NF-κB activity. Proteins A20
and OTULIN cleave K63 and Met1 from their substrates, which
physiologically downregulate NF-κB signaling. Little is known
about its exact role in the non-canonical pathway (10–12).
Type I interferons (IFNα and IFNβ) are the major effector
cytokines against virus and intracellular pathogens. They induce
the transcription of certain IFN stimulated genes with the
subsequent viral clearance. Among the two IFN activating
mechanisms, one is mediated by TLRs that detect viral nucleic
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acids within endosomes and induce proinflammatory cytokines
and IFNα, and the other is mediated by cytosolic DNA and RNA
sensors. DNA sensing is carried out by nucleotidyl transferase
cyclic GMP-AMP synthase (cGAS), which produces cGAMP
that binds to STING (stimulator of IFN genes) and induces
transcription of IFNβ genes. RNA sensing is mediated by
RIG-1-like helicase, RIG-1, and MDA-5 with the subsequently
recruitment of MAVS (mitochondrial antiviral signal) and
activation of NF-κB. IFN interacts with its surface receptor IFN-α
and induces the STAT pathway, which induces the transcription
of IFN genes and promotes antiviral activity. In addition,
proteins regulating the synthesis or degradation of nucleic acids
such as TREX1, SAMHDI, and RNase H2 play an important
role in IFN genes activation. Immunoproteasomes are protein
complexes that degrade ubiquitinated intracellular proteins and
are implicated in cellular stress responses, as well as activating
IFN (11, 13).
IL-1-mediated and IFN type I-mediated autoinflammatory
diseases and their main genetic and pathogenic aspects are
illustrated in Figure 1.
Over time, different classifications of monogenic
autoinflammatory diseases have been proposed according
to molecular and etiopathogenic mechanisms involved (11, 15),
type of inheritance (16), genetic background and clinical
presentation (17, 18). Apart from FMF and CAPS, other well-
characterized monogenic inflammasomopathies comprise TNF
receptor-associated periodic syndrome (TRAPS), hyper-IgD
syndrome (HIDS), pediatric granulomatous arthritis (Blau
syndrome and early onset sarcoidosis), pyogenic arthritis,
pyoderma gangrenosum, and acne (PAPA), deficiency of IL-1
receptor antagonist (DIRA) and deficiency of interkeukin-
36 receptor antagonist (DITRA). All the monogenic
autoinflammatory diseases covered in this review classified
according to the major pathogenic mechanism are listed
in Table 1.
Polygenic or multifactorial autoinflammatory diseases
are defined as complex systemic disorders sharing an
autoinflammatory and sometimes autoimmune background,
with an unknown genetic cause. The most prevalent polygenic
conditions include Behçet disease, Schnitzler syndrome, periodic
fever with aphthous stomatitis, pharyngitis, and cervical adenitis
(PFAPA), systemic juvenile idiopathic arthritis (sJIA), adult
onset Still disease (AOSD), Crohn disease and synovitis, acne,
pustulosis, hyperostosis, and osteitis (SAPHO) (19).
Clinical features in autoinflammatory diseases are variable,
heterogeneous and nonspecific, since most of the symptoms are
often shared by different conditions. Common inflammatory
manifestations include recurrent fever, musculoskeletal
symptoms, abdominal and thoracic serositis, headache, ocular
inflammation, and mucosal and skin lesions (11).
Dermatologic involvement is common in monogenic
autoinflammatory diseases and may represent the predominant
and the initial event in some of them. Among all the cutaneous
lesions present in monogenic autoinflammatory diseases,
maculopapular, and urticarial rashes are by far the most
prevalent manifestations. However, the identification of skin
lesions as part of an autoinflammatory disease is often difficult
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FIGURE 1 | Principal genetic and pathogenic mechanisms in IL-1 (A) and IFN type 1 (B) mediated autoinflammatory diseases [From Shwin et al. (14), with permission].
AGS, Aicardi–Goutières syndrome; CANDLE, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature; CAPS, cryopyrin-associated
periodic syndrome (FCAS, familial cold autoinflammatory syndrome; MWS, Muckle–Wells syndrome; NOMID, neonatal-onset multisystem inflammatory disease);
DIRA, deficiency of interleukin-1 receptor antagonist; FMF, familial Mediterranean fever; MKD/HIDS, mevalonate kinase deficiency/hyperimmunoglobulinemia D and
periodic fever syndrome; NLRC4-MAS, NLRC4-associated macrophage activation syndrome; PRAAS, proteasome-associated autoinflammatory syndrome; PRR,
Pattern recognition receptor; SAVI, STING-associated vasculopathy with onset in infancy; SMS, Singleton–Merten syndrome; SPENCDI, Spodyloenchondrodysplasia
with immune dysregulation; TLRs, toll-like receptors; TRAPS, TNF receptor-associated periodic syndrome.
because of the potential wide spectrum of skin manifestations
in these conditions, and also because the severity or extension
of the cutaneous lesions may differ among patients with the
same disease. In addition, some patients may exhibit overlapping
skin manifestations. Consequently, differential diagnosis
of dermatologic findings may be difficult, even for trained
professionals. For instance, with regard to urticarial lesions,
differential diagnosis should include all CAPS forms and other
monogenic diseases in which urticariform features are the most
characteristic cutaneous findings, but it must also comprise other
monogenic autoinflammatory diseases presenting less frequently
with urticarial rashes (e.g., TRAPS and HIDS), and several
polygenic autoinflammatory diseases (e.g., Schnitzler syndrome,
sJIA, and adult onset Still disease) (20). Moreover, clinical and
histopathological data about dermatological involvement in
monogenic autoinflammatory diseases are still scarce (14).
CLASSIFICATION OF MONOGENIC
AUTOINFLAMMATORY DISEASES
ACCORDING TO THE CUTANEOUS
INVOLVEMENT
Several classifications based on clinical and histopathological
features of cutaneous manifestations have been proposed
for autoinflammatory diseases (6, 11, 15, 16, 21, 22). In
2017, Shwin et al. (14) divided monogenic autoinflammatory
diseases into seven categories according to the predominant
cutaneous lesion and the most clinically relevant aspect:
(1) Nonspecific maculopapular rashes with recurrent
episodic fever and abdominal pain; (2) Neutrophilic
urticaria; (3) Pustular skin rashes and episodic fevers;
(4) Vasculopathy and panniculitis/lipoatrophy syndromes;
(5) Vasculopathy and/or vasculitis with livedo reticularis
syndromes; (6) Autoinflammatory disorders with
granulomatous skin diseases; and (7) Other autoinflammatory
syndromes (14).
Because other cutaneous and mucosal lesions have been
described to occur in monogenic autoinflammatory diseases, the
current review propose a new classification that includes nine
dermatologic categories:
1) Maculopapular rashes or inflammatory plaques;
2) Urticarial rashes;
3) Pustular, pyogenic, or neutrophilic dermatosis-like rashes;
4) Panniculitis or subcutaneous nodules;





The main monogenic autoinflammatory diseases are divided
in these nine groups and depicted in Table 2. By using this
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Inflammasomopathies FMF MEFV AR Pyrin GOF
TRAPS TNFRSF1A AD TNF receptor 1 LOF
HIDS/MKD MVK AR Mevalonate kinase LOF
CAPS NLRP3 AD NLRP3/cryopirin GOF
NLRC4-AD
(FCAS4)
NLRC4 AD NLRC4 GOF
PAPA PSTPIP1 AD CD2BP1 GOF
DIRA IL1RN AR IL-1 receptor antagonist LOF
Majeed syndrome LPIN2 AR Lipin-2 LOF
PAAND MEFV AD Pyrin GOF
NAIAD NLRC1 AR/AD NLRP1 LOF
PFIT WDR1 AR WD40 repeat protein LOF
CAIN CEBPE AR C/EBPε GOF
NF-κB related diseases Blau syndrome/Early-onset
sarcoidosis
NOD2/CARD15 AD NOD2 GOF
NLRP12-AD
(FCAS2)
NLRP12 AD Monarch1 LOF
Otulipenia/ORAS
(Ubiquinopathy)
OTULIN AR Otulin LOF
HA20
(Ubiquinopathy)
TNFAIP3 AD A20 LOF
HOIL-1 deficiency
(Ubiquinopathy)
HOIL1 AR HOIL1 LOF
CARD-14 psoriasis CARD14 AD CARD14 GOF
NFKB1-AD NFKB1 AD p50/p105 LOF
RELA haploinsufficiency RELA AD RelA LOF
ADAM17 deficiency ADAM17 AR TACE LOF
Interferonopathies CANDLE/PRAAS syndrome PSMB8 AR β5i subunit of the
proteasome
LOF
SAVI TMEM173 AD STING GOF
Familial chilblain lupus TREX1
SAMHD1
TMEM173












AR Proteins involved in
intracellular degradation or





SPENCDI ACP5 AR TRAP LOF
SMS IFIH1 and DDX58 AD MDA5 and RIG-1 GOF
Other DADA2 CECR1 AR ADA2 LOF
cytokine-signaling DITRA IL36RN AR IL-36 receptor antagonist LOF
diseases H syndrome SLC29A3 AR hENT3 LOF
PLAID (FCAS3) / APLAID PLCγ2 AD PLCγ2 GOF
Vibratory Urticaria ADGRE2 AD ADGRE2 LOF
AP1S3 and
autoinflammatory psoriasis
AP1S3 Not clear AP1S3 LOF
(Continued)
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AR IL10 and IL10 receptor LOF
AGS, Aicardi-Goutières syndrome; APLAID, autoinflammation and PLCγ2-associated antibody deficiency and immune dysregulation; CAIN, C/EBPε-associated autoinflammation
and immune impairment of neutrophils; CANDLE, chronic atypical neutrophilic dermatitis with lipodystrophy and elevated temperature syndrome; CAPS, cryopyrin-associated
periodic syndrome; DADA2 deficiency of adenosine deaminase 2; DIRA, deficiency of IL-1 receptor antagonist; DITRA, deficiency of the IL-36 receptor antagonist; dNTPs,
deoxynucleoside triphosphate; FMF, familial Mediterranean fever; GOF, gain-of-function; HA20, haploinsufficiency of A20; HIDS/MKD, hyper-IgD syndrome/Mevalonate kinase
deficiency; IL-10, interleukin 10; LOF, loss-of-function; MDA-5, melanoma differentiation-associated gene 5; NFKB1-AD, NFKB1-associated autoinflammatory diseases; NLRC4-
AD, NLRC4-associated autoinflammatory diseases; NLRP12-AD= NLRP12-associated autoinflammatory disease; ORAS= OTULIN-related autoinflammatory syndrome; PAAND,
pyrin-associated autoinflammation with neutrophilic dermatosis; PAPA syndrome, pyogenic sterile arthritis, pyoderma gangrenosum and acne syndrome; PFAPA, periodic fever,
aphthous stomatitis, pharyngitis and cervical adenitis; PFIT, Autoinflammatory periodic fever, immunodeficiency, and thrombocytopenia; PLAID, PLCγ2-associated antibody deficiency
and immune dysregulation; RIG-1, retinoic-acid-inducible gene; SAVI, STING-associated vasculopathy with onset in infancy; SMS= Singleton-Merten syndrome; SPENCDI,
Spondyloenchondrodysplasia with immune dysregulation; TRAPS, TNF receptor-associated periodic syndrome.
dermatologic classification, this review intends to focus on
dermatological and dermatopathologic aspects of monogenic
autoinflammatory diseases.
Maculopapular Rashes or Inflammatory
Plaques
Familial Mediterranean Fever (FMF)
FMF is the most frequent monogenic autoinflammatory disease
caused by mutations in the MEFV gene, which encodes pyrin.
Such mutations produce a constitutive activation of pyrin and
lead to an uncontrolled release of IL-1β and IL-18 (23). FMF
is classically inherited with an autosomal recessive fashion.
However, an autosomal dominant pattern has also been described
(24, 25). The most relevant pathogenic mutations, such as
M694V, M694I, M680I, and V726A, are commonly placed in the
exon 10 ofMEFV gene (26).
FMF is clinically characterized by recurrent and self-
limited inflammatory attacks lasting for 48–72 h with a
variable periodicity (27). High fever (38–40◦C) and serositis
as abdominal and chest pain are constantly present. Large
joints involvement and erysipeloid rash affecting the limbs are
also quite common. Febrile protracted myalgia, pericarditis,
scrotal pain, and lymphocytic meningitis may also occur. During
attacks, acute phase reactants such as C-reactive protein (CPR),
serum amyloid protein (SAA), erythrocyte sedimentation rate
(ESR), and fibrinogen are significantly increased and tend to
normalize during asymptomatic periods. Secondary amyloidosis,
usually involving the kidneys, is the most common long-term
complication, which is usually associated with a more severe
disease or colchicine-resistant disease (14, 26).
Colchicine is the treatment of choice to control disease
activity and to prevent the attacks. Colchicine also prevents the
development of amyloidosis. In cases of proved intolerance or
resistance to colchicine, anti-IL-1 agents have demonstrated
efficacy in controlling disease activity and amyloidosis
development. While canakinumab has been recently approved
by the US Food and Drug Administration (FDA) and
European Medicines Agency (EMA) (28), anakinra has also
been proved to be useful, either with a continuous or on demand
administration (29).
Dermatologic manifestations
Erysipeloid-like erythema is considered the pathognomonic
lesion of FMF and consists of an uni- or bilateral well-defined,
tender, erythematous, and edematous plaque, usually smaller
than 15 centimeters, localized below the knee and on the dorsal
aspect of the feet (Figure 2). Recurrences tend to occur in the
same place, usually after long walking distances, and tend to
subside within 24–48 h. It is common among Turks and Jews
patients and those carrying the M694V mutation, with a variable
frequency, ranging between 3 and 46% of FMF patients (30).
Other cutaneous lesions include diffuse palmoplantar
erythema and purpuric papules involving the face, trunk, and
extremities (31). FMF patients have an increased incidence of
associated systemic vasculitis, such as IgA vasculitis (Henoch-
Schönlein purpura), polyarteritis nodosa and Behçet disease
(31, 32).
Cutaneous histopathology
Erysipeloid-like plaques are histologically characterized by
slight edema of the superficial dermis and sparse perivascular
infiltrates with lymphocytes, neutrophils, histiocytes, and nuclear
dust. Blurring of the capillary walls is frequent. Direct
immunofluorescence shows deposits of IgM, C3, and fibrinogen
in the capillary walls of the papillary dermis (30). Slight changes
of acanthosis and hyperkeratosis in the epidermis have also been
described (33).
TNF Receptor-Associated Periodic Syndrome
(TRAPS)
TRAPS is the most frequent autosomal dominant
autoinflammatory disease. Mutations in the TNFRSF1A
gene, encoding TNF receptor 1, induce an overproduction of
IL-1β (11). T50M and cysteine mutations are associated with
an earlier and more severe disease presentation and long-term
development of complications, such as amyloidosis. Variants
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TABLE 2 | Classification of monogenic autoinflammatory diseases based on the
main cutaneous manifestation.
1 Maculopapular rashes or
inflammatory plaques
Familial Mediterranean Fever (FMF)
TNF receptor-associated periodic syndrome
(TRAPS)





2 Urticarial rashes Cryopyrin-associated periodic syndromes (CAPS)
NLRP12-associated autoinflammatory disease
(NLRP12-AD)





3 Pustular, pyogenic or
neutrophilic
dermatosis-like rashes
Pyogenic sterile arthritis, pyoderma gangrenosum
and acne (PAPA)
Syndromic forms of pyoderma gangrenosum
Deficiency of IL-1 receptor antagonist (DIRA)
Deficiency of IL-36 receptor antagonist (DITRA)
CARD-14 mediated psoriasis (CAMPS)
Majeed syndrome




AP1S3 and autoinflammatory psoriasis




Blau syndrome / Early-onset sarcoidosis
Chronic atypical neutrophilic dermatitis with
lipodystrophy and elevated temperature (CANDLE)
5 Vasculitis or
vasculopathy
Deficiency of adenosine deaminase 2 (DADA2)
STING-associated vasculopathy with onset in
infancy (SAVI)
Familial chilblain lupus
Aicardi-Goutières syndrome (AGS) 1-7
Spodyloenchondrodysplasia with immune
dysregulation (SPENCDI)
6 Hyperkeratotic lesions NLRP-1 associated disease (NAIAD)
7 Hyperpigmented lesions H syndrome
8 Bullous lesions Autoinflammation and PLCγ2-associated antibody
deficiency and immune dysregulation (APLAID)
9 Aphthous lesions Haploinsufficiency of A20 (HA20)
Autoinflammatory periodic fever, immunodeficiency
and thrombocytopenia (PFIT)
C/EBPε-associated autoinflammation and immune
impairment of neutrophils (CAIN)
NFKB1-associated Behcet-like disease
RELA haploinsufficiency
Monogenic forms of inflammatory bowel disease
(IL-10 signaling defects)
such as R92Q and P46L generally lead to a milder disease with a
later onset (2).
TRAPS usually occurs in children as recurrent and irregular
febrile episodes with generalized myalgia, arthralgia, abdominal
FIGURE 2 | Erysipeloid lesion in a leg of a patient with FMF. Written informed
consent was obtained from the patient for the publication of this image.
pain, ocular lesions (conjunctivitis, uveitis, and periorbital
edema) and skin involvement (16, 34). Attacks may be
spontaneous or triggered by infections and other stress
situations (35).
Acute phase reactants, including CRP, ESR, and ferritin,
are usually increased during attacks and subside after them.
Secondary amyloidosis may occur in 25% of patients, mostly in
those untreated (14, 34).
On demand use of non-steroidal anti-inflammatory drugs
(NSAID) and glucocorticoids during attacks may improve
symptoms in 40% of patients. With regard to anti-TNF agents,
etanercept is the only proving efficacy in controlling attacks, since
infliximab, and adalimumab have been associated with severe
paradoxical reactions. IL-6 blockade with tocilizumab may also
be of benefit in some cases. IL-1 inhibition seems to be the
treatment of choice in TRAPS patients (36, 37). Anakinra is
effective in most cases, administered either continuously or on
demand (38), and canakinumab has been recently approved by
the FDA and the EMA as first line therapy (28).
Dermatologic manifestations
About 80% of patients present with skin lesions. The most
frequent is the painful erythema that consists of a migratory,
centrifugal, erythematous, tender, non-purpuric, and well-
demarcated plaque overlying migratory myalgia. The differential
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diagnostic of these erythematous lesions comprises cellulitis
plaque or panniculitis of the limbs (14–16). Other manifestations
include (16) urticaria-like plaques, generalized serpiginous
plaques, and small-sized vessel vasculitis (16, 32, 39, 40).
Cutaneous histopathology
Histological specimens of TRAPS are characterized by a mild to
massive perivascular and interstitial lymphocytic and monocytic
infiltrate (CD3+, CD4+, CD8+, CD68+, CD79a–, and CD20–)
in edematous areas of the superficial and deep dermis, with no
evidence of multinucleated macrophages nor granulomatous or
leukocytoclastic vasculitis. Direct immunofluorescence reveals
deposits of IgM and C3 at the dermal-epidermal junction or
diffuse interstitial deposits of IgA, G, and C3. Perivascular C3 and
C4 deposition in the dermis is also described (14, 16, 34, 39, 41).
Hyper-IgD Syndrome (HIDS)
HIDS and mevalonic aciduria (MA) represent parts of the
spectrum of the mevalonate kinase (MVK) deficiency (MKD)
(2, 42). Both diseases are inherited with an autosomal recessive
pattern and caused by mutations in the MVK gene, which
encodes MVK, an enzyme involved in the synthesis of non-
steroidal isoprenoids and also in the caspase activation pathway
(14, 43–45). The amount of residual enzymatic activity correlates
inversely with phenotype severity. V377I and I268T are the
most frequent pathogenic mutations. Most HIDS patients
are heterozygous for two different variants. The presence of
homozygous I268T mutations is associated with MA, the most
severe phenotype (42).
MA has a neonatal onset with repeated attacks of fever
accompanied with severe ocular and neurologic involvement,
musculoskeletal abnormalities associated with growth
retardation and dysmorphic features, hepatosplenomegaly,
lymphadenopathy, and cutaneous lesions (46). HIDS is clinically
characterized by an early onset of monthly or bimonthly
recurrent febrile attacks lasting from 3 to 7 days. Other typical
features include cervical or generalized lymphadenopathies,
prominent oral aphthae, arthralgia or non-erosive arthritis of
large joints, abdominal pain, and hepatosplenomegaly. Attacks
of systemic and cutaneous symptoms are occasionally triggered
by infections, vaccines, or trauma (47).
Acute phase reactants, IgD and IgA levels are usually
elevated during attacks. An increase of urinary mevalonic
acid levels during attacks is considered a specific marker for
MKD. Secondary amyloidosis has been found in about 3% of
patients (47).
Glucocorticoids at high doses are useful to control attacks
in some patients, but most of them will require biologic
therapy to avoid glucocorticoid adverse events. Among biologics,
etanercept may improve symptoms in more than 50% of patients.
However, IL-1 blockers are effective in the majority of cases (37).
Anakinra has been proved to be useful in continuous or on
demand administration (48) and canakinumab has been recently
approved by the FDA and the EMA for HIDS treatment (28).
Tocilizumab has been reported effective in some cases refractory
to previous treatments (49).
Dermatologic manifestations
Skin involvement occurs in about 70% of MKD patients
(47). Cutaneous lesions are heterogeneous and typically consist
of non-specific maculopapular or morbilliform rashes. Small
erythematous macules, papules, nodules, or cellulitis-like plaques
are also frequent. Erythema nodosum and urticarial lesions
have also been described, as well as petechiae or purpura
resembling IgA vasculitis, erythema elevatum diutinum, and
Sweet’s syndrome (16, 31, 32, 50). Bipolar aphthae are present in
almost 50% of patients (47).
Cutaneous histopathology
MKD cutaneous lesions are histologically variable. Endothelial
swelling and perivascular inflammatory infiltrate are the main
changes in a skin biopsy. In addition, signs of leukocytoclastic
or necrotizing vasculitis, Sweet-like lesions, erythema elevatum
diutinum, or erythema nodosum may also be observed. Direct
immunofluorescence may show perivascular and linear deposits
of IgD and C3 along the basal membrane (14, 51).
Otulipenia
Otulipenia, also known as OTULIN-related autoinflammatory
syndrome (ORAS), is an autosomal recessive autoinflammatory
disease due to mutations in the FAM105B gene, which encodes
OTULIN, a Met-1 specific deubiquitinase that acts as a negative
regulator of the NF-κB signaling pathway (10).
Clinically these patients present with an early-onset of
prolonged recurrent episodes of fever, erythematous skin
rash with nodules, arthralgia, abdominal pain, diarrhea,
lymphadenopathy, and elevated acute phase reactants (10).
Treatment with TNF inhibitors is very effective in controlling
disease activity (10).
Dermatologic manifestations
A painful erythematous rash with skin nodules is the most
frequent cutaneous manifestation. Other features include
pustular rash, lipoatrophy, and panniculitis (10, 52).
Cutaneous histopathology
Skin biopsies show different types of panniculitis and
neutrophilic dermatosis. Small and medium-sized vessel
vasculitis have also been reported (10, 52).
HOIL-1 Deficiency
HOIL-1 deficiency is an autosomal recessive disease caused
by mutations in the HOIL1 gene, which encodes HOIL1,
a component of the linear ubiquitination chain assembly
complex (LUBAC). These mutations result in destabilization of
LUBAC complex with an impairment of the IL-1β dependent
NF-κB activation in fibroblasts. However, myeloid cells, in
particular monocytes, are hyperreactive to IL-1β. Therefore, the
consequences of human HOIL-1 and LUBAC deficiencies for
IL-1β responses differ between cell types (10).
HOIL-1 deficiency is clinically characterized by an early-onset
of recurrent episodes of fever with gastrointestinal symptoms,
such as abdominal pain, vomiting, and diarrhea with blood and
mucus, and also lymphadenopathy, respiratory distress, failure
to thrive, and muscular amylopectinosis (storage of abnormal
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glycogen that leads to intracellular glycogen inclusions), which
is complicated by myopathy and cardiomyopathy. Recurrent
bacterial infections secondary to immunodeficiency features,
including hyper-IgA syndrome and memory B-cell defects
with antibody production deficiency and impaired response
to vaccines have been reported. Inflammatory symptoms are
accompanied by elevated acute phase reactants during flares
(10, 53).
Dermatologic manifestations
Eczematous lesions, erythroderma, and exfoliative dermatitis
occurred in different patients with HOIL-1 deficiency.
Vaccination-induced subcutaneous inflammatory lesions
have also been described (10, 53).
Cutaneous histopathology
No data regarding HOIL1 deficiency and cutaneous histology
is available.
Urticarial Rashes
Cryopyrin-Associated Periodic Syndromes (CAPS)
CAPS or cryopirinopathies comprise three autosomal dominant
conditions with different disease severity. The mildest form
is familial cold autoinflammatory syndrome (FCAS), the
intermediate phenotype is Muckle-Wells syndrome (MWS),
and the most severe form is neonatal-onset multisystem
inflammatory disease (NOMID), also known as chronic infantile,
neurologic, cutaneous and articular (CINCA) (54). All CAPS
are caused by mutations in the NLRP3 gene, which encodes
NLRP3 protein or cryopyrin and lead to constitutive activation
of NLRP3 inflammasome and IL-1β overproduction. However,
more than half of CINCA/NOMID cases are produced
by de novo mutations. While the presence of pathogenic
mutations predicts a more severe phenotype with neurologic
complications and sensorineural hearing loss, low penetrance or
uncertain significance variants are associated with milder disease
phenotypes (11, 54).
Common clinical features to all CAPS forms include an
early disease onset with fever or low-grade fever episodes,
fatigue, urticarial rash, musculoskeletal symptoms, and ocular
involvement as conjunctivitis and uveitis. During attacks, acute
phase reactants tend to be elevated (14, 17). In FCAS, attacks
are typically triggered by cold exposure and self-limited in
<24 h. In MWS, attacks usually last 1–2 days and sensorineural
hearing loss and amyloidosis are frequently developed, mostly
in undiagnosed or untreated patients. CINCA/NOMID is
characterized by a sustained systemic inflammatory response
that included persistent fever, diffuse urticarial lesions and
severe osteoarticular, ocular and neurologic involvement, usually
leading to deforming and irreversible sequelae.Without a prompt
directed treatment, CINCA/NOMID becomes a disabling and
lethal disease.
Anti-IL-1 agents are considered the treatment of choice
for CAPS (39, 55, 56) since anakinra and canakinumab are
approved by the FDA and the EMA for CAPS treatment.
While IL-1 blockade does not appear to influence established
joint and bone damage, its early administration seems to
FIGURE 3 | Generalized urticarial rash with erythematous flat wheals without
surrounding flare on the left arm (A) and trunk (B) in a patient with
Muckle-Wells syndrome. Written informed consent was obtained from the
patient for the publication of this image.
reduce the risk of developing (or improve them when
developed) amyloidosis, hearing loss, and neurologic
complications (57).
Dermatologic manifestations
A non-pruritic, somewhat symmetrical and evanescent urticarial
rash involving the trunk and extremities, usually sparing the
head, is the most frequent cutaneous event in CAPS (Figure 3)
(20, 31, 58). As for CAPS, in other monogenic autoinflammatory
diseases with urticarial lesions, hives are usually more flattened,
painful or burning, and last longer than those of chronic
spontaneous urticaria. In addition, they may also appear
as erythematous patches or even solid lesions. Angioedema
is not usually present. Although FCAS attacks are usually
triggered by cold exposure, contact with cold objects does not
cause a disease attack, and therefore, the ice cube test is
negative (20).
Cutaneous histopathology
Neutrophilic urticarial dermatosis is the clinicopathological term
used to describe dermatologic and histological findings in CAPS,
which are different from those observed in ordinary neutrophilic
urticaria. CAPS skin biopsies usually show no edema or mild
dermal edema of the papillary dermis with a perivascular
and neutrophilic infiltrates with limited leukocytoclasia (32)
(Figure 4). The presence of neutrophilic epitheliotropism
(neutrophils around or within eccrine glands or ducts, or inside
the epidermis) is rather characteristic although it can be seen in
other entities (Figure 5) (59). Interstitial neutrophilic infiltrates
have also been described (14, 60, 61).
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FIGURE 4 | Histopathology of a wheal from a patient with Muckle-Wells syndrome (MWS). (A) Dermal interstitial and perivascular infiltrates composed of lymphocytes
and neutrophils consistent with neutrophilic urticaria. (B) Perivascular infiltrate in detail.
FIGURE 5 | Skin biopsy in a patient with familial cold autoinflammatory
syndrome (FCAS) due to a somatic mutation in the NLRP3 gene. There are
dermal neutrophilic infiltrates between the collagen bundles and around blood
vessels with presence (inset) of neutrophils around and within eccrine glands.
NLRP12-Associated Autoinflammatory Disease
(NLRP12-AD)
NLRP12-AD, also known as FCAS2, is an autosomal dominant
autoinflammatory disease caused by mutations in the NLRP12
gene, which encodes Monarch-1 (31) and play a role in the
activation of NF-κB and caspase 1 signaling pathways (62).
Similarly, to FCAS, patients with NLRP12-AD present with
recurrent episodes of high fever triggered by cold exposure,
lasting for 2–10 days, every 3–4 weeks. Fever is commonly
accompanied by arthralgia, myalgia, abdominal pain, headache,
lymphadenopathy, oral aphthae, and skin rash. Sensorineural
hearing loss is the most common long-term complication. Acute
phase reactants are elevated during attacks (63, 64).
Glucocorticoids, antihistamines, and NSAIDs may be useful
in mild cases. Severe cases seem to respond to anakinra and also
to anti-IL-6 and anti-TNFα agents (64, 65).
Dermatologic manifestations
Cold exposure usually induces the attack and cutaneous
manifestations consisting of an evanescent urticarial rash
involving the trunk, extremities and face. An erythematous malar
rash (64) and cutis laxa (66) have also been described to occur.
Contrary to FCAS, FCAS2 rashes tend to be itchy. The ice cube
test is consistently negative (63, 64).
Cutaneous histopathology
No data about NLRP12-AD cutaneous histology is available.
However, histopathological findings are expected to be similar to
those described in CAPS.
PLCγ2-Associated Antibody Deficiency and Immune
Dysregulation (PLAID)
PLAID, also known as FCAS3, is an autosomal dominant
autoinflammatory disease due to mutations in the PLCγ 2 gene,
encoding phospholipase Cγ2 (PLCγ2), a transmembrane
signaling enzyme with phospholipase activity. Cellular
dysregulation is produced by a signaling reduction on
pathways depending of PLCγ2, which are enhanced at low
temperatures. B cells, NK cells, and mast cells are involved in the
inflammatory dysregulation (67). De novo mutations have been
also reported (68).
Clinical manifestations include an early onset of recurrent
cutaneous lesions triggered by cold exposure and immunological
abnormalities, such as the presence of antinuclear antibodies
(ANA), immunoglobulin deficiencies (mostly IgM and IgA),
elevated IgE levels, and decreased amounts of switched memory
B-cells resembling a primary immunodeficiency, which leads to
an increased susceptibility to infections (68).
Avoiding cold temperatures is the main preventive therapy.
Depending on the history of repeated infections, intravenous
immunoglobulins and prophylactic antibiotics can be used (69).
Directed therapies with PLCγ2 inhibitors are not available
yet (70).
Dermatologic manifestations
The main cutaneous manifestation of PLAID is a recurrent
itchy cold-induced evaporative urticaria, since it appears in
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cold-sensitive regions of the body after generalized exposure to
cold air or evaporative cooling, but not after contact with cold
objects. Lesions subside with an increase in temperature (69, 70).
Other less common features include a neonatal ulceration of
the nasal tip, which may show spontaneous regression or have
a progressive and destructive course, and small papules and
erosions on the fingers and toes that tend to resolve without
sequelae. Granulomatous-like inflammatory lesions, usually
presenting as red-brown, indurated and scaly plaques and
nodules of the skin sparing warm regions, such as flexural
surfaces and skinfolds (69), and infantile epidermolysis-bullosa-
like eruption, initially generalized and later evolving to recurrent
erythematous plaques and vesiculopustular photosensitive
lesions (71) have also been reported.
Cutaneous histopathology
Urticarial lesions show an increased number of perivascular
and interstitial mast cells, which appear degranulated after
cold exposure (72). Biopsies of granulomatous lesions
reveal well-delineated, non-necrotizing, non-caseating, or
sarcoid-type granulomas, but also diffuse, poorly-defined
granulomatous inflammation, particularly in the superficial
dermis. Granulomatous infiltrates are composed by nodular
foci of CD68+ epithelial histiocytes and multinucleated
giant cells surrounded by a mild CD4/CD8+ lymphocytic
infiltrate and scattered eosinophils. Perineural and lymph nodes
granulomatous inflammation may also be observed (69).
NLRC4-Associated Autoinflammatory Diseases
(NLRC4-AD)
NLRC4-associated macrophage activation syndrome (NLRC4-
MAS) and familial cold autoinflammatory syndrome 4
(FCAS4) are part of NLRC4-AD (73). Both phenotypes are
autosomal dominant diseases caused by mutations in the NLRC4
gene, encoding NLRC4, which lead to a constitutive NLRC4
inflammasome activation resulting in an increased secretion
of IL-1β and IL-18. IL-18 is found at extremely high levels in
patients with NLRC4-MAS and may persist elevated, even in the
absence of clinical activity (74, 75).
The most severe clinical phenotype (NLRC4-MAS) is
dominated by a multisystemic inflammation starting in the
first year of life with symptoms of chronic inflammatory
bowel disease, MAS, or symptoms resembling CINCA/NOMID.
Enterocolitis tends to subside over time (74). The mildest
phenotype (FCAS4) usually starts at age of three with attacks
after exposure to cold stimuli of urticaria, arthralgia, ocular
inflammation, and fever in half of cases, in absence of visceral
involvement. Although CRP levels are elevated, in severe cases,
ESR values tend to decrease as the disease progresses.
Glucocorticoids and anakinra may be useful in most mild
cases (76). IL-18 inhibitors and anti-interferon-gamma inhibitors
have shown good response in severe cases (73, 75).
Dermatologic manifestations
Skin manifestations range from an unspecific rash to cold
urticaria, evanescent urticarial, or linear erythematous lesions
(74). While children commonly present with urticarial
rash alone, in adult patients, urticarial lesions, and painful
erythematous nodules on lower extremities are the most frequent
signs (77, 78).
Cutaneous histopathology
NLRC4-AD histopathological findings are scarce. Nodular
lesions show deep dermal and subcutaneous lymphohistiocytic
infiltrates with septal and lobular panniculitis. Perivascular
lymphocytic infiltrates without vasculitic changes have also been
described. Direct immunofluorescence has not detected IL-1β
staining (77).
Vibratory Urticaria
Vibratory urticaria is an autosomal dominant autoinflammatory
disease caused by mutations in the ADGRE2 gene, which
encodes ADGRE2, a member of the epidermal growth factor
seven transmembrane that acts as a cell surface receptor
with two subunits, the extracellular α subunit and the
transmembrane β subunit. It is predominantly expressed in
leukocytes, especially in neutrophils and macrophages, but also
in mast cells. The endogenous ligand of ADGRE2 is dermatan
sulfate, which is the predominant glycosaminoglycan of the
skin. The mutated ADGRE2 receptor undergoes autocatalytic
cleavage, producing an extracellular subunit that non-covalently
binds a transmembrane subunit with destabilization of the
autoinhibitory subunit interaction and sensitization of mast cells
to IgE-independent vibration-induced degranulation. Therefore,
transitory high histamine serum levels seem to be responsible for
the clinical manifestations in these patients (79).
Localized pruritic hives after repetitive vibratory or friction
stimuli are the principal manifestations of the disease.
Occasionally, cutaneous lesions may be accompanied by
systemic symptoms (79).
Dermatologic manifestations
Skin lesions consist of localized pruritic hives, angioedema,
erythema, and pruritus caused by repetitive physical stimulation.
Cutaneous changes may appear from a few minutes to an hour
after the vibratory stimulus. In prolonged or intense mechanical
expositions, urticarial lesions may be associated with a more
severe angioedema or systemic symptoms, such as headache,
fatigue, facial flushing, and metallic taste. While dermographism
is not present in patients with vibratory urticaria, urticarial rash
can be provoked by stimulating the forearm with a laboratory
vortex (79).
Cutaneous histopathology
Skin biopsies of vibration-induced lesions show a significant
release of mast cell granular content in cases samples compared
to controls (79).
Pustular, Pyogenic, or Neutrophilic
Dermatosis-Like Rashes
Pyogenic Arthritis, Pyoderma Gangrenosum, and
Acne Syndrome (PAPA)
PAPA is an autosomal dominant autoinflammatory disease
caused by mutations in the PSTPIP1 gene, encoding
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CD2BP1 or PSTPIP1 (80). Although the pathogenesis is
not completely understood, PSTPIP1 seems to play a role in
inflammasome activation and overproduction of IL-1β and
IL-18 (81).
Clinical manifestations start at pediatric age with recurrent
flares of erosive, sterile, and deforming arthritis of the elbows,
ankles, and knees, leading to early joint destruction. Skin
ulcers and severe acne occur during adolescence. Fever is rare
and frequency of flares tends to decrease with age. Increased
acute phase reactants and leukocytosis are observed during
attacks (82).
Glucocorticoids, IL-1 blockers, and anti-TNF agents may be
useful in treating arthritis and pyoderma gangrenosum (83).
After PAPA description in 1997 by Lindor et al. (84),
other pyoderma gangrenosum-associated syndromes (85) with
autoinflammatory background and a late-onset have been
described. Those include PASH (86–89), PAPASH (83, 90),
PsAPASH (91), and PASS (92). These PAPA-like syndromes are
summarized in Table 3.
Dermatologic manifestations
Skin involvement includes pyoderma gangrenosum and
severe cystic acne, which gets worse with puberty. Pyoderma
gangrenosum may occur spontaneously or be triggered
by trauma (pathergy) and starts as a violaceous tender
papule, nodule or a sterile pustule that rapidly expands
with necrosis of the surrounding tissue, and finally results in
a poor-healing and painful ulcer with undermined borders
(Figure 6). Granulation tissue, necrosis or purulent discharge
is common in the middle of the ulcer. Cribriform scarring is a
hallmark of the disease and may help with the diagnostic (93).
Psoriasiform lesions and rosacea-like eruptions have also been
reported (94).
Cutaneous histopathology
The typical histological feature consists of central sterile
neutrophilic infiltrates in the dermis that becomes with mixed
cellularity in the peripheral areas (Figure 7) (14, 93).
Deficiency of IL-1 Receptor Antagonist (DIRA)
DIRA is an autosomal recessive autoinflammatory disease caused
by mutations in the IL1RN gene, encoding IL-1 receptor
antagonist (IL-1RA) (95). This mutations lead to the absence of
IL-1RA and produce an overactivity of IL-1 (57).
DIRA is clinically characterized by a neonatal-onset of
chronic-recurrent flares with cutaneous pustulosis, joint swelling,
and bone pain due to painful multifocal aseptic osteomyelitis,
long bone periostitis, epiphyseal overgrowth, and secondary
skeletal malformations. Interstitial lung disease, vasculitis of the
central nervous system, thrombosis, and respiratory distress are
much less frequent manifestations (96, 97). Although fever is
usually absent, acute phase reactants are constantly elevated
during attacks. If untreated, the disease tends to evolve to
multiorgan failure with a high mortality rate (57, 96).
Anakinra at doses of 1–5 mg/kg/day remains the treatment of
choice for DIRA since it produces a fast and complete clinical and
biological resolution in the majority of patients (98).
Dermatologic manifestations
Newborn children present with localized or generalized
erythematous plaques and overlying sterile pustules sparing
palms and soles. These plaques may evolve to diffuse
desquamation resembling ichthyosiform lesions. Nail changes
with pitting and onychomadesis, similar to those experiencing in
psoriasis, are frequent. Oral lesions such as ulcers and vesicular
stomatitis may also occur (97).
Cutaneous histopathology
Histological findings resemble those of pustular psoriasis
and skin biopsies show acanthosis and hyperkeratosis of the
epidermis with extensive epidermal and dermal neutrophilic
infiltrates developing pustules around hair shafts. Vasculitis in
subcutaneous tissue adjacent to the bone have also been described
(96, 99).
Deficiency of IL-36 Receptor Antagonist (DITRA)
DITRA is an autosomal recessive autoinflammatory disease
caused by mutations in the IL36RN gene, which encodes IL-36
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FIGURE 6 | Different stages of pyoderma gangrenosum in PAPA. (A) Initial lesion with an erythematous and tender plaque with a central sterile pustule; (B) Ulceration
with necrotic borders; and (C) Poor-healing and painful ulcer with undermined borders and cribriform scarring. Written informed consent was obtained from the
patients for the publication of these images.
FIGURE 7 | Histopathology of pyoderma gangrenosum in a PAPA patient. (A) Dense neutrophilic infiltrate with upper dermis edema. (B) Neutrophilic infiltrate in detail.
receptor antagonist (IL36Ra) (100). Thesemutations are involved
in NF-κB activation and overproduction of proinflammatory
cytokines such as IL-36 and IL-8 (100, 101). In recent years, late-
onset cases have been described in patients carrying heterozygous
mutations (101).
DITRA is clinically included in generalized pustular psoriasis.
These patients may have a pediatric and adult onset consisting of
irregular episodes of high-grade fever, generalized pustulosis, and
asthenia, with elevated acute phase reactants and leukocytosis.
Attacks have been reported to be triggered by infections,
pregnancy, and menstruation (100). Several authors have
suggested that patients with early-onset generalized pustular
psoriasis without concomitant psoriasis vulgaris are often
diagnosed with DITRA (102).
DITRA is currently included in the group of
autoinflammatory keratinization diseases (AIKD), a term
first used in 2017 to cluster those disorders characterized
by keratinized lesions caused by an autoinflammatory
mechanism (103).
Conventional topical and systemic therapies used for
psoriasis may also be useful in DITRA patients (16). Anakinra
(anti-IL-1), adalimumab, infliximab (anti-TNFα), ustekinumab
(anti-IL-12/23), and secukinumab (anti-IL-17) have shown
efficacy in isolated cases (104–106). Recently, a phase 1 clinical
trial in patients with generalized pustular psoriasis treated with a
single intravenous dose of a monoclonal antibody against the IL-
36 receptor has shown promising results by reducing the severity
of the disease over a 20-week period, regardless of the presence of
the IL36RN mutation (107).
Dermatologic manifestations
Cutaneous lesions resemble those of generalized pustular
psoriasis and consist of a diffuse erythematous skin eruption
that tends to be rapidly covered by pustules with subsequent
desquamation (Figure 8). Skin eruptions may mimic all forms
of psoriasis ranging from psoriasis vulgaris to acrodermatitis
continua (100, 108).
Cutaneous histopathology
Histological features are indistinguishable from classical pustular
psoriasis and include epidermal hyperplasia with acanthosis,
irregular papillomatosis, subcorneal spongiform pustules,
compact orthokeratosis, or parakeratosis and neutrophilic
infiltration (Figure 9). Immunohistochemistry of the dermis
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shows superficial perivascular infiltrates of CD8 and CD3T cells,
macrophages and neutrophils (100, 108).
CARD-14 Mediated Psoriasis (CAMPS)
CAMPS is an autosomal dominant inherited disease due to
mutations in the CARD14 gene encoding CARD14. Such
mutations produce an overactivation of NF-κB pathway (109).
Keratinocytes show high levels of CARD14 (110). CAMPS is
currently classified as AIKD (103).
Disease presentation may vary among monogenic psoriasis,
pustular psoriasis, psoriatic arthritis, or pityriasis rubra
pilaris. Features of systemic inflammation are usually absent.
Therapeutic options are mainly the same as those used for
treating psoriasis and DITRA (111–113).
Dermatologic manifestations
Clinical manifestations are mostly cutaneous presenting as a
plaque and pustular psoriasis. Other diseases, such as pityriasis
FIGURE 8 | Clinical features of a patient with DITRA with a heterozygous
mutation in the IL36RN gene. The clinical picture started in adulthood with
flares of diffuse erythematous plaques covered with pustules that often
involved the whole body (A,B). The episodes were often triggered by bacterial
infections. Written informed consent was obtained from the patient for the
publication of this image.
rubra pilaris or acute generalized exanthematous pustulosis, have
also been associated with CARD14 mutations. Disease extension
may vary from localized to generalized, as well as severity, which
may range from mild to severe (111, 113–115).
Cutaneous histopathology
Skin biopsies show histopathological features of psoriasis or
pityriasis rubra pilaris (116).
Majeed Syndrome
Majeed syndrome is an autosomal recessive autoinflammatory
disease caused by mutations in the LPIN2 gene, which encodes
phosphatase lpin2 (117). Mutated LPIN-2 induces NLRP3
activation with the consequent IL-1β overproduction (118).
The clinical triad is characterized by the early onset of chronic
recurrent multifocal sterile osteomyelitis (CRMO), congenital
dyserythropoietic anemia and neutrophilic skin lesions (119).
Other manifestations during attacks include fever and swelling
of large joints. Growth retardation and permanent flexion
contractures are long-term complications in untreated patients
(120). Abnormal laboratory tests include raised acute phase
reactants levels, anemia, and variable leukocytosis.
Treatment with NSAIDs and glucocorticoids may be
useful in controlling CRMO-related pain. Anti-TNF agents,
bisphosphonates, and interferon gamma show variable success
rates. IL-1 blockers have been useful in controlling inflammatory
manifestations (121–123).
Dermatologic manifestations
Inflammatory dermatoses are the most frequent cutaneous
symptoms, and may occur as neutrophilic dermatoses and
erythematous and scaly plaques. The prototypic findings are
Sweet syndrome-like lesions, seen as erythematous plaques,
pseudovesiculous or target lesions (120, 124). CRMO has
also been associated with generalized pustulosis, palmoplantar
psoriasis, pyoderma gangrenosum, acne, recurrent subcutaneous
abscesses, and SAPHO syndrome (31, 120, 125–128).
FIGURE 9 | Histology of DITRA shows epidermal acantosis with edema and dilated blood vessels in the papillary dermis. There is epidermal spongiosis with the
presence of neutrophils migrating through the epidermis (A,B). In the most superficial part of the epidermis (inset-B) there is a subcorneal pustule that is formed
through the aggregation of neutrophilic spongiform pustules.
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Cutaneous histopathology
Skin histopathology displays edema of the papillary dermis with
dense dermic neutrophilic infiltrates. A bone biopsy usually
shows subacute and chronic inflammatory changes (129).
Pyrin-Associated Autoinflammation With
Neutrophilic Dermatosis (PAAND)
PAAND is an autoinflammatory disease caused by mutations in
the MEFV gene, the same gene responsible for FMF. However,
contrarily to the autosomal recessive but inconstant pattern
observed in FMF patients, PAAND has an autosomal dominant
inheritance with complete penetrance. PAAND mutations
(S242R and E244K) are associated with pyrin inflammasome
activation (130).
PAAND has a childhood-onset characterized by recurrent
febrile episodes lasting for several weeks accompanied with
arthralgia, myalgia and cutaneous inflammatory lesions. During
attacks, acute phase reactants and circulating proinflammatory
cytokines (IL-1β, IL-6, TNF-α, and IL-1Ra) levels are normally
increased (130).
Treatment with IL-1 blockers has shown a rapid control
of clinical and laboratory abnormalities. Infliximab and
adalimumab have been used with success in anakinra-resistant
patients (130).
Dermatologic manifestations
Severe neutrophilic dermatoses in PAAND have a wide
spectrum of presentation, including pustular acne, pyoderma
gangrenosum, sterile skin abscesses, neutrophilic small vessel
vasculitis, severe hidradenitis suppurativa, and neutrophilic
panniculitis (32, 130, 131).
Cutaneous histopathology
Histopathology reveals an spared epidermis and dense dermal
neutrophilic infiltrates both interstitial and perivascular (131).
Other Novel Psoriasiform Monogenic
Autoinflammatory Diseases
Singleton-merten syndrome (SMS)
SMS is an autosomal dominant transmitted disease caused by
mutations in IFIH1 or DDX58 genes. The resulting proteins
(melanoma differentiation associated protein 5 [MDA5] and
retinoic-acid-inducible gene I [RIG-I], respectively) are involved
in type I interferon induction pathways (132).
Clinical manifestations occur after childbirth and are
characterized by dental dysplasia, tendon rupture, osteoporosis,
arthropathy, neurologic abnormalities, aortic calcification, and
glaucoma. Cutaneous involvement as localized or generalized
psoriasis is present in the majority of patients (132).
As in other type I interferonopathies, the use of a Janus kinase
(JAK) inhibitor has been useful in a SMS patient (132).
ADAM17 deficiency
ADAM17 deficiency is considered an autoinflammatory disease
(6) caused by autosomal recessive mutations in the ADAM17
gene, encoding TNF-α converting enzyme (TACE), which is
necessary for the cleavage and secretion of TNF-α, epidermal
growth factor, transforming growth factor alpha (TGF-α), and
some desmogleins (6, 133).
Clinical features were described in two consanguineous
siblings with neonatal-onset of pustular psoriasis followed by
chronic bloody diarrhea and cardiomyopathy. Skin lesions
were characterized by perioral and perianal erythema with
fissuring and a generalized pustular rash that evolved to
psoriasiform erythroderma, with flares of erythema, scaling, and
widespread pustules. Cutaneous infections were frequent. Other
dermatologic manifestations included hair abnormalities (short
or fragile hair and wiry eyelashes and eyebrows), and thickened
nails with frequent episodes of paronychia. Dermatopathology
revealed infiltrates of T cells in the epidermis. CD3+ T cells
were located around the skin follicles and in the epithelium,
CD4+ T cells in the perifollicular region and CD8+ T cells
in the epithelium at the neck of the follicle. B cells (CD20+),
natural killer cells (CD56+), or neutrophils were scarce within
the infiltrates (133).
Treatment with acitretin, ciclosporin, methotrexate, and
adalimumab has not been useful in patients with ADAM17
deficiency. However, anti-IL1 and anti-IL6 therapy may be
potential agents since peripheral-blood mononuclear cells from
patients overproduced IL-1β and IL-6 after lipopolysaccharide
stimulation (133).
AP1S3 and autoinflammatory psoriasis
Pustular psoriasis may be caused by mutations in the AP1S3
gene encoding AP1S3, a protein implicated in autophagosome
formation, which is elevated in keratinocytes. Its deficiency
disrupts keratinocyte autophagy and causes abnormal
accumulation of p62, an adaptor protein mediating NF-kB
activation, with subsequent up-regulation of IL-1 signaling and
overexpression of IL-36. The inheritance pattern is not clear
since patients with de novo mutations and with a mutated allele
from an unaffected parent have been reported. Treatment with
IL-36 blockade has demonstrated to reverse skin lesions (134).
Although inflammatory symptoms such as arthritis may be
present, pustular psoriasis is the most prominent clinical feature.
This may be localized to the palms and soles (palmar plantar
pustulosis) or to the toes and fingertips (acrodermatitis continua
of Hallopeau), but it may also be generalized (134).
Panniculitis or Subcutaneous Nodules
Blau Syndrome and Early-Onset Sarcoidosis
Blau syndrome and early-onset sarcoidosis are the two forms
of pediatric granulomatous arthritis caused by mutations in the
NOD2/CARD15 gene encoding NOD2. While Blau syndrome
is inherited in an autosomal dominant manner, early-onset
sarcoidosis is the spontaneous form, caused by the novo
mutations (135).
In both disorders, symptoms onset occurs during the
first decade of life with the sequential, but not constant,
triad of maculopapular rash, non-erosive arthritis of wrists,
hands, elbows and ankles, and uveitis. Other less frequent
manifestations include fever, large and small vessel vasculitis,
interstitial lung disease, cranial neuropathies, and granulomatous
involvement of salivary glands, kidneys, spleen, and liver
Frontiers in Immunology | www.frontiersin.org 14 October 2019 | Volume 10 | Article 2448
Figueras-Nart et al. Dermatology and Dermatopathology of Monogenic Autoinflammatory Diseases
(136, 137). Laboratory studies are typically normal, although
elevated ESR and angiotensin-converting enzyme levels and
hypergammaglobulinemia have been reported (137).
With regard to treatment, high-dose glucocorticoids may be
useful for inflammatory symptoms. Limited reports have shown
effectiveness with thalidomide, methotrexate, cyclosporine and
other conventional immunosuppressants, together with anti-IL-
1 and anti-IL-6 agents. However, anti-TNF blockers (infliximab
and adalimumab) seem to be the drugs associated with better
responses (15, 135–137).
Dermatologic manifestations
Skin involvement is the most prominent and the earliest
expression of the disease, which is manifested as an erythematous
maculopapular fine scaly rash on the trunk and extremities,
resembling an ichthyosiform exanthema. Progressively it
becomes tan-colored with lichenoid characteristics and dirty
scaly appearance. This later stage tends to last longer (22, 138).
Erythema nodosum-like lesions, pityriasis lichenoides, leg
ulcers, and leukocytoclastic vasculitis have also been observed
(136, 139).
Cutaneous histopathology
Histopathology of the cutaneous lesions shows non-caseating,
sarcoid-type granulomas in the subpapilar dermis with a variable
number of lymphocytes and eosinophils (138). Biopsies from
purpuric lesions display vasculitis, and leg ulcers can show
both, granulomatous infiltrates and chronic granulation with
mononuclear infiltration in the fat tissue (139).
Chronic Atypical Neutrophilic Dermatitis With
Lipodystrophy and Elevated Temperature Syndrome
(CANDLE)
CANDLE syndrome, also called proteasome associated
autoinflammatory syndrome (PRAAS), is an autosomal
recessive autoinflammatory disease caused by mutations
in the PSMB8 gene, which encodes the β5i subunit of the
immunoproteasome (5, 11). PSMB9, PSMA3, PSMB4, and
POMP are other proteasome genes recently identified as also
causing CANDLE/PRAAS (140). This condition is considered
an interferonopathy since mutant genes cause defective
proteasome/immunoproteasome assembly and accumulation
of ubiquitinated proteins that induce intracellular stress and
increased IFN-1 production through JAK signaling pathway
(141, 142).
Classical manifestations include neonatal onset of recurrent
or persistent high-fever, cutaneous lesions, and facial and
generalized lipodystrophy. Arthralgia, muscle atrophy,
hepatosplenomegaly, lymphadenopathy, and inflammatory
involvement of other territories, such as ocular, meningeal,
epididymis and parotids, are also common (143). Raised acute
phase reactants are constant and muscle and hepatic enzymes
are frequently elevated. Positive ANA and antineutrophil
cytoplasmic antibodies (ANCA) may be present without
pathogenic significance (144).
Glucocorticoids, conventional immunosuppressive drugs, and
biologic agents, such as anti-TNF, anti-IL-1, or anti-IL-6 have
been used without complete response (143, 144). Baricitinib,
a JAK inhibitor that prevents the expression of IFN-induced
genes and the autoinflammatory loop, has shown efficacy in
CANDLE/PRAAS patients (145).
Dermatologic manifestations
Perinatal-onset fever attacks are accompanied by annular
erythemato-violaceous edematous plaques on trunk and
extremities, and stable violaceous erythemas on the perioral and
periorbital areas. Most of these lesions resolve within few days
or weeks leaving purpuric pigmentation, but recurrences are
common. Other less frequent manifestations include violaceous
nodules, hirsutism, and acanthosis nigricans. The development
of progressive lipoatrophy of the face, extremities, and trunk
occurs in the late phase of the disease (22, 143, 144).
Cutaneous histopathology
Histopathology of cutaneous lesions is characterized by dense
interstitial and perivascular atypical-looking (because of the
presence of mitotic figures) mononuclear infiltrates with
karyorrhexis in the deep dermis and fat tissue. Neutrophils
and eosinophils may also be observed within the infiltrates.
Immunohistochemistry shows strong and diffuse positivity for
myeloperoxidase, lysozyme, CD68, and CD45, which confirms
the myeloid lineage of the infiltrate by revealing the presence of
macrophages and histiocytes. T cells and B cells, identified by
positivity for CD3, CD45RO, and CD20, are also present to a
lesser extent (143, 144).
Vasculitis or Vasculopathy
Deficiency of Adenosine Deaminase 2 (DADA2)
DADA2 is an autosomal recessive autoinflammatory disease
caused by mutations in the CECR1 gene, encoding ADA2 (146,
147). ADA2 acts as a growth factor in the myeloid lineage
promoting differentiation into anti-inflammatory macrophages,
and has also a role in the development and maintenance of
endothelial cells. Mutant ADA2 promotes vascular damage by
affecting endothelial cells and inducing neutrophil-driven cell
damage (146, 147).
DADA2 patients commonly exhibit persistent or recurrent
fever, skin lesions (mostly livedo reticularis or racemosa and
subcutaneous nodules), peripheral neuropathy and vascular
lesions secondary to distal ischemia or hemorrhage of the affected
territories, especially involving the brain. Disease phenotype
is frequently indistinguishable from polyarteritis nodosa. Oral
aphthae, arthralgia and hepatosplenomegaly are also frequent.
Acute phase reactants are increased during attacks and the
presence of variable peripheral blood cytopenias and low
immunoglobulin levels contribute to develop a certain degree
of immunodeficiency. Although disease typically occurs in early
childhood, later-onset cases have also been described (146, 147).
Although high-dose glucocorticoids can be effective
in some patients, low-dose glucocorticoids, conventional
immunosuppressive drugs, anti-CD20 therapy and anti-IL-1 and
anti-IL6 blockers do not seem to provide a clear benefit. However,
anti-TNF agents, in particular etanercept, have demonstrated to
control systemic inflammatory manifestations and progression
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FIGURE 10 | Livedo racemosa on the lower limbs in a patient with DADA2.
Written informed consent was obtained from the patient for the publication of
this image.
of vascular disease, in the absence of normalization of ADA2
enzyme activity. To date, allogeneic hematopoietic stem cell
transplantation is the only therapy that has demonstrated to cure
the disease (146–148).
Dermatologic manifestations
The most frequent cutaneous lesions are livedo reticularis or
racemosa (Figure 10) and subcutaneous nodules. Pediatric and
adult presentations may have a phenotype resembling cutaneous
arteritis or polyarteritis nodosa refractory to conventional
immunosuppressive therapy. Raynaud syndrome, digital
necrosis, ulcers, and erythema nodosum may also occur
(146, 147, 149).
Cutaneous histopathology
Skin biopsies are characterized by dermal interstitial neutrophilic
infiltrates which stain positive for myeloperoxidase and CD68
confirming the existence of macrophages and a perivascular
lymphocytic infiltrate. Livedo and nodular lesions may display
non-granulomatous necrotizing medium-sized vessels vasculitis.
However, leukocytoclastic vasculitis or panniculitis have also
been reported (32, 146, 147, 149).
STING-Associated Vasculopathy With Onset in
Infancy (SAVI)
SAVI is an autosomal dominant autoinflammatory disease caused
by mutations in the TMEM173 gene encoding STING, an
indirect sensor of cytosolic DNA that activates IRF3 and induces
transcription of IFN-1 related genes. Mutant STING results in
overactivation of IRF3 and transcription of IFNβ (150).
SAVI is clinically characterized by a neonatal-onset of
recurrent febrile attacks with cutaneous rash, small-vessel
vasculitis, and interstitial lung disease. During flares, acute phase
reactants are elevated and low-titer autoantibodies, such as ANA,
ANCA, and antiphospholipid antibodies, are frequent (150, 151).
As in other interferonopathies, IFN-1 pathway blockade with
JAK inhibitors, in particular baricitinib, seems to be effective in
SAVI, since glucocorticoids, conventional immunosuppressive,
and anti-cytokines agents have not demonstrated efficacy (145).
Dermatologic manifestations
Skin is the initial territory involved in SAVI. Lesions are caused
by vasculitic changes with subsequent tissue damage and are
manifested as violaceous, scaly and atrophic plaques affecting
hands, cold-induced ulcerative distal lesions and erythemato-
violaceous nodules on the cheeks, ears and nose, nail dystrophy,
distal digital gangrene, and nasal septum perforation. Other
cutaneous lesions such as telangiectasia, pustules, blisters,
erythematous plaques may also occur, mostly on acral sites (14).
Cutaneous histopathology
Dermatopathology shows medium and small-vessel vasculitis
with dense neutrophilic infiltrates and karyorrhexis in the vessel
wall, as well as fibrin endovascular microthrombi (32, 151).
Biopsies of telangiectatic plaques show perivascular infiltration
by lymphocytes and neutrophils with leukocytoclasia, without
involvement of the vessel walls (14).
Familial Chilblain Lupus
Familial chilblain lupus or TREX1-associated systemic lupus
erythematosus is an autosomal dominant autoinflammatory
disease caused by either loss-of-function mutations in
TREX1 and SAMHD1 genes or gain-of-function mutations
in the TMEM173 gene, both leading to type I IFN
overproduction (152–154).
Clinical manifestations consist of early-onset of
mucocutaneous lesions and arthralgia, with occasional periodic
fever and infrequent increased inflammatory markers. Low-titer
autoantibodies, including ANA and anti-C1q-autoantibodies are
usually present. Successful treatment with JAK inhibitors has
been described (153, 155).
Dermatologic manifestations
Patients present with cold-induced chilblain lesions at acral
locations (fingers, toes, nose, and ears) with subsequent ischemia
and ulceration of these regions. Nails can show dystrophy
or onychomadesis. Nailfold capillaroscopy may appear with
irregular capillary loops and tortuous appearance. Livedo
reticularis, malar rash, photosensitivity, and oral and nasal ulcers
have also been described (152–154).
Cutaneous histopathology
Histological examination of skin reveals perivascular
lymphohistiocytic infiltrates along with expression of the
type I IFN-induced myxovirus resistance protein A within the
endothelial cells (153).
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Aicardi-Goutières Syndrome (AGS)
AGS comprise a group of seven monogenic autoinflammatory
diseases, most of which are inherited with an autosomal recessive
pattern, caused by mutations in several genes encoding proteins
involved in intracellular degradation or sensing of nucleic
acids. TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1,
ADAR1, IFIH1, and DDX58 are the genes involved in AGS.
Mutations in these genes induce high levels of IFNα, both
in blood and cerebrospinal fluid, which are thought to be
responsible for systemic and cerebral tissue damage (156). In
addition, dyschromatosis symmetrica hereditaria is an autosomal
dominant skin disease caused by mutations in the ADAR1
gene consisting of hyper- and hypo-pigmented macules on the
dorsal aspects of the extremities. Patients with homozygous
or compound heterozygous ADAR1 mutations may present
with a combination of AGS6 and dyschromatosis symmetrica
hereditaria (157).
All forms of AGS share several features in common,
such as a neonatal-onset encephalopathy consisting in
basal ganglia calcifications, spasticity, dystonia, progressive
cerebral atrophy, and microcephaly, as well as fever and
hepatosplenomegaly (14). Abnormal laboratory results include
lymphocytosis and elevated IFNα levels in cerebrospinal fluid.
Patients may develop some autoimmunity features resembling
systemic lupus erythematosus, such as arthritis, lymphopenia,
thrombocytopenia, and ANA positivity (156).
No traditional treatment options, including glucocorticoids
and conventional immunosuppressants and anti-cytokines
agents, are useful. As for previous interferonopathies, JAK
inhibitors seem also to control AGS activity (145, 156, 158, 159).
Dermatologic manifestations
Skin involvement comprises chilblain lesions on the feet, hands,
and ears, digital vasculitis, generalized skinmottling, lipoatrophy,
panniculitis, and acral necrotic lesions (14, 156, 160).
Cutaneous histopathology
No data regarding cutaneous histopathology is available in AGS.
Spondyloenchondrodysplasia With Immune
Dysregulation (SPENCDI)
SPENCDI is an autosomal recessive autoinflammatory disease
caused mutations in the ACP5 gene encoding tartrate-resistant
phosphatase. The lack of activity of this enzyme leads to a
constitutive gain-of-function of osteopontin, a multifunctional
protein involved in bone remodeling and immune regulation
causing autoimmunity through a type I interferon expression
signature (161).
SPENCDI is clinically characterized by bone dysplasia with
subsequent growth retardation, and neurologic manifestations,
such as cerebral atrophy, intracranial calcifications, seizures, and
spastic paraparesis. Systemic and organ-specific autoimmune
diseases are commonly present. These include systemic lupus
erythematosus, antiphospholipid syndrome, Sjögren syndrome,
Raynaud’s disease, inflammatory myositis, arthritis, vitiligo,
hypothyroidism, hemolytic anemia, and thrombocytopenia.
Consequently, autoimmune markers are also frequently
present, including positive ANA, anti-DNA antibodies, and
hypocomplementemia (161).
Glucocorticoids, chloroquine, and other additional
immunosuppressive agents, such as cyclophosphamide,
azathioprine, mycophenolate mofetil, and rituximab have
been used with good results (161).
Dermatologic manifestations
Cutaneous manifestations include severe eczema, Raynaud’s
phenomenon, distal sclerodermatous/acrocyanotic changes, and
leukocytoclastic vasculitis presenting with purpuric lesions.
Livedo reticularis and occlusive vasculitis leading to digital auto-
amputation have also been described. Capillaroscopy may reveal
edema and sludging or disappearance of parallel loops of some
dilated capillaries (161).
Cutaneous histopathology
The skin biopsy from a patient with SPENCDI confirmed a non-
specific leukocytoclastic vasculitis with perivascular neutrophilic
infiltrate, without deposition of complement or immunoglobulin
at direct immunofluorescence (161).
Hyperkeratotic Lesions
NLRP-1 Associated Disease (NAIAD)
NAIAD is an autoinflammatory disease inherited with a
recessive or dominant pattern due to mutations in the NLRP1
gene, which encodes NLRP1 protein. NLRP1 is the central
inflammasome in the skin. Mutations in PYRIN or LRR
domains lead to constitutive NLRP1 inflammasome activation
and IL-18 production (138). NAIAD is currently categorized as
AIKD (103).
Patients present with infantile-onset attacks of recurrent
fever lasting 3–4 days, accompanied by hyperkeratotic lesions,
polyarticular arthritis and chronic relapsing infections. Blood
tests show high CRP levels during flares, low-titer of ANA,
vitamin A deficiency, and raised transitional B cells (162).
Treatment with vitamin A and acitretin has been associated with
clinical improvement.
Dermatologic manifestations
Most patients show disseminated erythematous follicular
hyperkeratosis. Cases of familial keratosis lichenoides chronica
(also considered an AIKD), associated with multiple self-
healing palmoplantar carcinoma, as well as larynx involvement
resembling human papillomavirus infection have been reported
in NAIAD patients (162, 163).
Cutaneous histopathology
Skin biopsy shows orthokeratotic hyperkeratosis with
papillomatosis, acanthosis and hypergranulosis. Numerous
dyskeratotic cells sparse throughout the epidermis, without
involving the basal layer, have been observed (162).
Hyperpigmented Lesions
H Syndrome
H syndrome is an autosomal recessive autoinflammatory disease
caused by mutations in the SLC29A3 gene encoding ENT3 (164).
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This syndrome is referred to as “H syndrome” to
describe some of the disease hallmarks: hyperpigmentation,
hypertrichosis, hepatosplenomegaly, heart anomalies, hearing
loss, and hypogonadism. Therefore, the disease is clinically
characterized by progressive sclerotic skin lesions, cardiac
anomalies, short stature, and childhood-onset sensorineural
hearing loss. Other manifestations include scrotal masses,
azoospermia, hepatosplenomegaly, micropenis, dilated scleral
vessels, exophthalmos, facial telangiectasia, and camptodactyly
(164, 165). Laboratory tests reveal high ESR values and growth
hormone deficiency (164).
Most treatments, including glucocorticoids, colchicine,
cytotoxic immunosuppressants, IFNα, anakinra, canakinumab,
adalimumab, and radiotherapy, are associated with an inadequate
response (164).
Dermatologic manifestations
Cutaneous involvement starts with progressive sclerotic,
hyperpigmented plaques on the lower limbs with hypertrichosis,
and less frequently with ichthyotic desquamation. These lesions
usually appear on the inner aspect of the thighs and progress to
the abdomen, genitalia, ankles and feet, with sparing of the knees
and buttocks. The presence of plaques in axillae and trunk is
infrequent (164, 165).
Cutaneous histopathology
Dermatopathology is characterized by an increase of melanocytes
with acanthosis in the basal layer and sclerodermiform changes
with interstitial macrophagic infiltrates in the dermis and fat
tissue. Perivascular infiltrates of lymphocytes, mast cells and
plasma cells are also noted. Emperipolesis (cell engulfment
phenomena) may be occasionally observed (22, 165).
Bullous Lesions
Autoinflammation and PLCγ2-Associated Antibody
Deficiency and Immune Dysregulation (APLAID)
APLAID is an autosomal dominant autoinflammatory disease
caused by two missense mutations (S707Y and L848P) in the
PLCγ 2 gene. Despite being produced by the same gene that
PLAID, mutants in APLAID result in hyperactivation of PLCγ2
signaling pathway and are associated with a different disease
phenotype (71, 166).
APLAID patients present with early-onset recurrent
attacks of blistering skin lesions, eye inflammation with
ocular hypertension, inflammatory bowel disease, arthralgia,
and sinopulmonary infections caused by a mild humoral
immunodeficiency. Acute phase reactants tend to be normal and
switched memory B-cells are almost absent. Contrary to PLAID,
APLAID is not characterized by cold-induced urticaria and the
presence of circulating autoantibodies (71).
While TNF-blockers have not shown efficacy, high-dose
glucocorticoids, and anakinra have been reported to control
inflammatory symptoms (71).
Dermatologic manifestations
Early-onset recurrent blistering lesions resembling
epidermolysis-bullosa is the most common picture. Later
in life, these lesions tend to evolve to recurrent erythematous
plaques and vesiculopustular lesions that get worse with sun and
heat exposure. Cellulitis-like plaques and granulomata, as well as
cutis laxa, have also been described (70, 71, 166). More recently,
three cases with different presentation have been reported: a
newborn patient with generalized erythematous papules evolving
to vesicles, pustules, and crusts involving face, gluteal region, and
extremities (167) and two patients of 6 and 14 years-old with a
papulovesicular skin rash with granuloma formation and cutis
laxa (168).
Cutaneous histopathology
A biopsy from a plaque lesion showed a dense dermal interstitial
and perivascular mixed inflammatory infiltrate composed of
lymphocytes, histiocytes, eosinophils, and karyorrhectic nuclear
debris (71).
Aphthous Lesions
Haploinsufficiency of A20 (HA20)
HA20, also known as monogenic Behçet-like disease, is
an autosomal dominant autoinflammatory disease caused by
mutations in the TNFAIP3 gene encoding protein A20.
Mutated A20 results in increased NF-κB signaling and NLRP3
hyperactivity (11, 169).
The clinical picture of HA20 is characterized by the
triad of orogenital ulcers, ocular inflammation and non-
deforming polyarthritis (170). Abdominal pain, pharyngitis,
pericarditis, retinal vasculitis, and central nervous system
vasculitis are also frequent manifestations (32, 171). Several
organ-specific and systemic autoimmune diseases have been
associated with HA20. Some of them include Hashimoto
thyroiditis, type 1 diabetes mellitus, neutrophilic dermatosis,
erythema nodosum, pseudofolliculitis, central nervous system
vasculitis, Kawasaki disease, IgA vasculitis, nephrotic syndrome,
idiopathic thrombocytopenic purpura, or interstitial lung disease.
Acute phase reactants are increased during flares and low-
titer autoantibodies may be present in cases with autoimmune
diseases (171).
Treatment with colchicine, glucocorticoids, methotrexate and
thalidomide may be useful. Refractory cases to previous drugs
have been reported to respond to anti-TNFα, anti-IL-1, and
anti-IL-6 agents (170, 171).
Dermatologic manifestations
Oral, genital, and gastrointestinal non-scarring ulcers are the
most frequent manifestations (Figure 11). Skin involvement
is characterized by pustular or vesicular rashes, acne, dermal
abscesses, mild desquamation, and hyperkeratosis. Pathergy test
can be positive in some patients (170, 171).
Cutaneous histopathology
Histological data of the skin is limited. The presence of
an epidermal infiltrate of lymphocytes and neutrophils
with extensive intradermal mucin accumulation and scarce
inflammatory infiltrates has been reported (171).
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FIGURE 11 | Oral aphtous lesion in a patient with HA20. Written informed
consent was obtained from the patient for the publication of this image.
Autoinflammatory Periodic Fever, Immunodeficiency,
and Thrombocytopenia (PFIT)
PFIT is an autoinflammatory disease caused by a homozygous
missense mutation in the actin regulatory gene WDR1,
which encodes WDR1. Mutant WDR1 is thought to facilitate
assembly of pyrin inflammasome, leading to excessive IL-18
production (172).
PFIT clinical features include recurrent fever attacks, lasting
from 3 to 7 days and with 6–12 weeks periodicity. Fever is
accompanied by oral ulcers, intermittent thrombocytopenia and
cellular immunodeficiency, increasing the rate of infections.
Raised acute phase reactants, leukocytosis, hyperferritinemia,
and thrombocytopenia are observed during attacks (172).
Glucocorticoids, colchicine, conventional
immunosuppressive drugs, and anakinra have been associated
with poor responses. A case treated with an allogeneic
hematopoietic stem cell transplantation has been reported
with success (172).
Dermatologic manifestations
The most critical skin manifestation is the presence of
severe oral ulcers and inflammation that cause scarring and
microstomia (172).
Cutaneous histopathology
There are no reports regarding histopathological features in PFIT
skin lesions.
C/EBPε-Associated Autoinflammation and Immune
Impairment of Neutrophils (CAIN)
CAIN is an autosomal dominant autoinflammatory disease
caused by mutations in the CEBPE gene encoding the
transcription factor C/EBPε, which regulates both the
inflammasome and the interferome.
CAIN is characterized by a combination of autoinflammation,
immunodeficiency and neutrophil dysfunction. Disease onset has
been reported during adolescence and tends to subside after
menopause. The clinical presentation consists of periodic attacks
of abdominal pain and high fever during 4–5 days, every 2–4
weeks. Other manifestations during attacks include oral ulcers,
cutaneous abscesses, pyoderma gangrenosum, intra-abdominal
granulomas, and upper respiratory tract infections.Mild bleeding
diathesis with frequent nosebleeds and hematomas after needle
sticks and surgical procedures have also been described. ESR
elevation is frequent.
In CAIN patients, blockade of IL-1β and anti–IL-18 are
candidate therapies, still untested (173).
Dermatologic manifestations
Crater-like buccal ulcers are the most frequent mucocutaneous
features. Severe recurrent tongue, gluteal, submandibular
abscesses, purulent paronychia, pyoderma gangrenosum, and
wounds with delayed healing have also been described.
Cutaneous histopathology
No information about dermatopathologic features in CAIN
lesions has been reported.
NFKB1-Associated Autoinflammatory Diseases
(NFKB1-AD)
NFKB1-AD comprise a group of three different autosomal
dominant diseases due to mutations in the NFKB1 gene. These
mutations affect the NK-κB subunits p50 and p105, resulting in
an increased expression of IL-1β and TNF in some cases (174).
Initial descriptions of patients with NFKB1 gene mutations
were associated with an immunodeficiency phenotype
consisting of recurrent respiratory tract infections leading
to chronic lung disease with bronchiectasis, diarrhea,
lymphadenopathy, splenomegaly, recurrent autoimmune
phenomena (hemolytic anemia, thrombocytopenia, and
leukopenia), hypogammaglobulinemia, deficient production of
specific antibodies, and decreased class-switched and memory B
cells (175, 176).
Subsequently, two additional autoinflammatory phenotypes
associated to different mutations in the NFKB1 gene have been
described in two families (177). The first autoinflammatory
phenotype is NFKB1-associated Behçet-like disease, which has
been associated with the non-truncating mutation H67R in the
NFKB1 gene. It was described in six individuals within the
same family presenting with clinical manifestations similar to
those observed in Behçet disease (mucosal ulcers, arthritis, and
abdominal pain) (177). Notably, mutations in NFKB1 affect
the same pathway as in HA20. However, Behçet-like disease
associated with NFKB1 mutations was also associated with
IgG-hypogammaglobulinemia, depletion of switched memory B
cells and increased susceptibility to respiratory tract infections,
thus overlapping somewhat with the immunodeficiency and
autoimmunity phenotype described first for NFKB1-associated
disease (175, 176). Behçet-like phenotype seems not to cause
canonical inflammasome overactivation in vitro, thus targeting
IL-1β and TNF might not be useful (177).
The second autoinflammatory phenotype is NFKB1-
associated sterile familial autoinflammatory necrotizing fasciitis
(FANF), which is caused by the truncating mutation R157X in
the NFKB1 gene. It was described in two brothers who presented
with recurrent, sterile, isolated necrotizing inflammation
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after tissue trauma caused by minor surgery, and rapidly
extending into muscle fasciae, thus corresponding to necrotizing
fasciitis. Patients had no other organ or systemic involvement
nor any obvious manifestations of immunodeficiency (177).
This mutation caused increased inflammasome activation in
vitro, suggesting that agents targeting IL-1β or TNF might
be useful in such autoinflammatory necrotizing fasciitis
patients (174).
Dermatologic manifestations
The most common cutaneous lesions in patients with NFKB1-
associated Behçet-like disease are mucosal aphthae affecting
oral mucosa, esophagus, and genitalia. Lesions consisting of
postoperative deep necrotizing fasciitis have been described in
two patients of the same family with FANF (177). Of note,
NFKB1-associated FANF lesions have been included in the
section of pustular, pyogenic or neutrophilic dermatosis-like
rashes in Table 2.
Cutaneous histopathology
Information about genital aphthae biopsy displayed a small vessel
vasculitis, similar to that seen in Behçet’s patients (177).
RELA Haploinsufficiency
RELA haploinsufficiency is an autosomal dominant
autoinflammatory disease caused by mutations in the RELA
gene, which encodes RelA, a subunit of NF-κB. The heterodimer
RelA/NF-κB1 constitutes the predominant form of NF-κB,
critical for cell survival. A biallelic requirement for RelA in
order to maintain the normal cell function in stromal and
epithelial cells, which is essential for mucosal integrity, has
been reported. However, lymphocyte function is preserved
in mice with RELA haploinsufficiency. This would explain
why these patients with an impaired NF-κB signaling and an
increased sensitivity to TNF have mucosal abnormalities without
immunodeficiency (178).
Clinically these patients present with mucosal ulcers and
gastrointestinal symptoms, such as abdominal pain, vomiting,
and diarrhea, which can resemble an inflammatory bowel disease.
Fever and elevated acute phase reactants are also present.
Treatment with glucocorticoids and TNF-α inhibitors have
shown efficacy (178).
Dermatologic manifestations
Oral and/or genital ulcers are the most common
mucocutaneous feature described in patients with RELA
haploinsufficiency (178).
Cutaneous histopathology
No information regarding cutaneous histopathological features
in RELA haploinsufficiency has been reported yet.
Monogenic Forms of Inflammatory Bowel Disease
Crohn’s disease and ulcerative colitis are considered
inflammatory bowel diseases (IBD), diseases with a polygenic
or multifactorial etiology, in which complex interactions
between genetic and environmental factors play an important
role. Although over 150 genetic loci are associated with IBD,
the genetic contribution toward heritability of the majority
of those loci is low. However, recent studies have reported
an increasing spectrum of human monogenic diseases that
can present with IBD-like intestinal inflammation. Most of
patients with those genetic defects present with very early
onset IBD (during early childhood). However, as occur in
polygenic IBD, in the monogenic forms, a variable penetrance
of the clinical phenotype has been similarly described, also
suggesting a role for modifier genes and/or gene–environmental
interactions (179).
Oral aphthae may occur in polygenic and monogenic forms
of IBD. With regard to monogenic forms, IL-10 signaling defects
associated with very early onset IBD is an autosomal recessive
monogenic autoinflammatory disease caused by mutations in
genes encoding IL-10 and IL-10-receptor. Clinical manifestations
start within the first 3 months of life and include bloody
diarrhea, abscesses, perianal fistula, folliculitis, oral aphthous
lesions and arthritis. The intermittent course of colitis with
deep ulcerations is also indistinguishable from that of Crohn
disease (179).
CONCLUSIONS
Cutaneous inflammatory lesions are commonly present
in most of monogenic autoinflammatory diseases. Among
them, non-specific maculopapular rashes and urticarial
lesions are the most frequent manifestations, which have
some differential traits regarding similar lesions without an
autoinflammatory cause. While the evidence of systemic
involvement will draw the attention toward an autoinflammatory
origin, a genetic test showing pathogenic mutations in
causal genes will confirm the diagnosis of a monogenic
autoinflammatory disease.
Because the information regarding skin manifestations is still
scarce, this review analyzes the most relevant histopathological
and clinical features of cutaneous involvement in monogenic
autoinflammatory diseases and groups the diseases based on
the predominant cutaneous lesions, which were divided in: (1)
maculopapular rashes or inflammatory plaques; (2) urticarial
rashes; (3) pustular, pyogenic, or neutrophilic dermatosis-like
rashes; (4) panniculitis or subcutaneous nodules; (5) vasculitis
or vasculopathy; (6) hyperkeratotic lesions; (7) hyperpigmented
lesions; (8) bullous lesions; and (9) aphthous lesions.
Therefore, the classification based on the predominant skin
lesion in patients in whom a monogenic autoinflammatory
disease is suspected may be a supporting tool to guide
final diagnosis.
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